Updated Jul 16, 2026
Allan Jonathan has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $2.19M.
Jonathan Allan serves as the General Counsel and Corporate Secretary at Stoke Therapeutics, Inc., a biotechnology company focused on RNA medicine. He has been involved in multiple SEC filings related to the company, indicating a significant role in its corporate governance.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 1.5K | $29.95 | $44K |
| 2026-03-24 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 601 | $34.41 | $21K |
| 2026-03-24 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 8.7K | $33.64 | $292K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 72 | $32.85 | $2K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 334 | $31.79 | $11K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 4.2K | $31.28 | $132K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 1.8K | $33.38 | $60K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 2.5K | $32.74 | $81K |
| 2026-03-17 | STOK | Stoke Therapeutics, Inc. | M — Option exercise | 12.0K | $0.00 | |
| 2026-03-17 | STOK | Stoke Therapeutics, Inc. | M — Option exercise | 6.0K | $0.00 | |
| 2026-03-17 | STOK | Stoke Therapeutics, Inc. | M — Option exercise | 7.5K | $0.00 | |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.3K | $31.76 | $74K |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 5.4K | $31.08 | $169K |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.0K | $31.33 | $31K |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 194 | $31.32 | $6K |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 824 | $30.76 | $25K |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | M — Option exercise [10b5-1] | 6.0K | $0.00 | |
| 2025-10-03 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 10.0K | $25.07 | $251K |
| 2025-10-03 | STOK | Stoke Therapeutics, Inc. | M — Option exercise | 10.0K | $9.15 | $92K |
| 2025-08-29 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 6.3K | $20.07 | $127K |
Jonathan Allan serves as the General Counsel and Corporate Secretary at Stoke Therapeutics, Inc., a biotechnology company focused on RNA medicine. He has been involved in multiple SEC filings related to the company, indicating a significant role in its corporate governance.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 22 open-market sales ($2.19M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Allan Jonathan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.